Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trial

Pioglitazone, an antidiabetic drug, also exerts several cardiometabolic benefits including antioxidant, anti-inflammatory, antihypertensive, vasoprotective and hypolipidemic effects. These pioglitazone-related benefits have been observed in different patient populations such as those with prediabetes, non-alcoholic fatty liver disease and type 2 diabetes mellitus (T2DM). With regard to cardiovascular (CV) morbidity and mortality, there is conflicting evidence.Recently, the Insulin Resistance Intervention after Stroke (IRIS) trial reported a significant pioglitazone-induced decrease in CV morbidity in patients with insulin resistance (IR) (but no T2DM) and a history of a recent ( ≤ 6months) ischemic stroke or transient ischemic attack (TIA).
Source: Journal of Diabetes and Its Complications - Category: Endocrinology Authors: Source Type: research